SS-31 (Elamipretide): Mitochondrial Peptide for Endurance?

SS-31 — known by its drug name elamipretide — is the peptide that finally crossed the line every other compound in this space is still waiting at: in September 2025 it became an FDA-approved drug. For a category built almost entirely on grey-market research chemicals, that is a genuinely big deal, and it is exactly why the marketing has gotten louder. But the approval is for an ultra-rare pediatric genetic disease affecting roughly 150 people in the United States — not for endurance, not for recovery, and not for anyone healthy. The gap between "first FDA-approved mitochondria-targeted drug" and "boosts your endurance" is the entire story here, and it is wider than the hype admits.

The honest headline first: SS-31/elamipretide is a cardiolipin-stabilizing mitochondrial peptide that, in September 2025, received FDA accelerated approval as FORZINITY for Barth syndrome — a rare inherited mitochondrial cardioskeletal disease — to improve muscle strength in patients weighing at least 30 kg. There is striking aged-mouse data showing it rapidly improves mitochondrial function and exercise capacity. But there is no controlled trial of SS-31 in healthy athletes, and the one large phase-3 trial in a broader muscle-disease population actually failed both its primary endpoints. Athletic use is off-label experimentation with an injectable drug, and most "SS-31" sold to consumers is not the approved product at all. Hold that frame against every claim below.

What SS-31 Actually Is

SS-31 belongs to a family of "Szeto-Schiller" peptides — small, cell-permeable, aromatic-cationic peptides engineered to concentrate inside the inner mitochondrial membrane, where they act as mitochondria-targeted antioxidants¹. That targeting is the whole point: instead of scavenging free radicals everywhere in the cell, SS-31 accumulates precisely where most cellular energy production — and most oxidative damage — happens.

Its mechanism is more specific than "antioxidant," though. SS-31/elamipretide binds reversibly to cardiolipin, a signature phospholipid of the inner mitochondrial membrane that the energy-producing machinery (the electron transport chain) depends on to stay properly organized. By binding cardiolipin, elamipretide helps preserve the folded architecture (the cristae) of the mitochondrion and protects that membrane under stress. Mechanistic work shows the cardiolipin-binding peptide elamipretide mitigates the fragmentation of cristae networks that follows mitochondrial injury². That cardiolipin connection is also exactly why Barth syndrome became its lead indication: Barth is caused by a tafazzin gene mutation that disrupts cardiolipin, so a cardiolipin-stabilizing drug is a mechanistically rational match.

The FDA Approval — Real, but Narrow

This is the part worth getting precisely right, because it is what separates SS-31 from every other peptide marketed to athletes.

On September 19, 2025, the FDA granted accelerated approval to elamipretide (brand name FORZINITY, from Stealth BioTherapeutics) — the first treatment ever approved for Barth syndrome and, notably, the first FDA-approved mitochondria-targeted therapeutic³. The approved indication is specific: to improve muscle strength in adult and pediatric patients weighing at least 30 kilograms who have Barth syndrome — a progressive, life-limiting, ultra-rare genetic mitochondrial disease that affects an estimated 150 people in the US³.

The approval rested on the TAZPOWER program — a randomized, double-blind, placebo-controlled phase 2/3 trial (with an open-label extension) of subcutaneous elamipretide in Barth syndrome patients⁴. Longer-term open-label data out to 168 weeks reported sustained effects on muscle and cardiac measures in that population⁵, and natural-history comparison work supported the efficacy case the FDA reviewed⁶.

Two things about "accelerated approval" matter for an honest reading. First, it is a pathway designed for serious diseases with unmet need, often based on a surrogate or intermediate endpoint, with confirmatory evidence still expected — it is a real approval, but a conditional one. Second, and more important for anyone reading this for athletic reasons: the indication is Barth syndrome, full stop. Nothing about this approval speaks to healthy, trained, or even ordinary unwell adults. A drug approved to help a child with a cardiolipin-deficiency disease regain muscle strength tells you nothing about whether it improves a healthy athlete's VO2max or recovery.

The Endurance Data — Striking, and Entirely in Aged Animals

So where does the "endurance peptide" reputation come from? Not from athletes — from mice, and specifically old mice.

The landmark finding came in 2013: a single SS-31 treatment rapidly improved mitochondrial energetics and skeletal-muscle performance in aged mice, restoring the redox balance and energy output of old muscle toward youthful levels within hours⁷. That speed and effect size is what made SS-31 famous. It was reinforced in 2019, when researchers showed that improving mitochondrial function with SS-31 reversed age-related redox stress and improved exercise tolerance in aged mice⁸. Later work added mechanistic depth — elamipretide improved ADP sensitivity in aged skeletal-muscle mitochondria, a core measure of how efficiently old muscle can ramp up energy production⁹ — and showed parallel rejuvenation effects in aged hearts¹⁰ and aged kidneys¹¹.

Read together, this is a genuinely impressive, coherent body of aging-reversal science. SS-31 appears to make old mitochondria behave more like young ones. But notice the pattern that runs through every one of these studies: the model is aged or diseased animals, and the effect is restoration of impaired function, not enhancement of healthy function. A peptide that brings a 24-month-old mouse's muscle back toward where it was at 6 months is correcting a deficit. That is a completely different claim from making an already-healthy, well-trained human run faster. We hold this exact line for the other "mitochondrial exercise mimetic" in this space — see our review of MOTS-c: the "exercise mimetic" peptide, where the same aged-rodent-to-athlete leap collapses under scrutiny.

The Trial That Doesn't Get Quoted: MMPOWER-3 Failed

Here is the data point the marketing leaves out, and it is the most important one for judging whether SS-31 "works."

Beyond Barth syndrome, elamipretide was tested in a much larger, broader population: primary mitochondrial myopathy (PMM) — people whose muscles are weakened by mitochondrial genetic defects. An earlier crossover study (MMPOWER-2) had hinted at a dose-dependent walking improvement¹², which fueled optimism. Then came MMPOWER-3, a large phase-3 randomized controlled trial of 218 patients published in Neurology in 2023. The result was unambiguous: elamipretide did not meet either primary endpoint — neither the six-minute walk distance nor the fatigue score improved versus placebo (6MWT difference -3.2 meters, p = 0.69)¹³. The drug was well tolerated, but on the outcomes that mattered, it failed.

This matters enormously for the endurance question. MMPOWER-3 is the closest thing that exists to a real-world test of "does SS-31 improve walking capacity and fatigue in people whose mitochondria need help?" — and in a rigorous, adequately powered trial, the answer was no. If elamipretide could not improve a six-minute walk in patients with diagnosed mitochondrial muscle disease, the prior probability that it boosts endurance in healthy athletes — who have no mitochondrial deficit to correct — is low, not high. The Barth approval succeeded on a narrower, cardiolipin-specific disease and different endpoints; it does not rehabilitate the general "mitochondrial endurance booster" claim that MMPOWER-3 directly tested and refuted.

What This Means for Athletes: Zero Human Performance Data

Put the pieces together and the athletic picture is stark. There is no published, controlled trial of SS-31/elamipretide in healthy athletes for any performance, endurance, or recovery outcome. None. The human evidence base is entirely in disease — an ultra-rare genetic condition where it was approved, and a broader muscle disease where it failed. The performance reputation is built on aged-mouse studies that, however striking, are about reversing age-related decline, not enhancing trained humans.

That makes athletic use textbook off-label experimentation — and with an unusual twist for this category: SS-31 is now simultaneously an FDA-approved drug and a grey-market research chemical, depending on where you get it. The approved product (FORZINITY) is a specialty drug for ~150 diagnosed Barth patients, not something a healthy lifter can obtain through normal channels. So in practice, "SS-31" sold to athletes online is almost always unregulated research-chemical material — meaning you cannot verify identity, purity, dose, or sterility of what is actually in the vial. That is the same supply problem we document across the category, from whether GH peptides are even safe and legal to vendor red flags and scams. And like any peptide marketed to enhance physical capacity, a tested athlete should assume it draws anti-doping scrutiny and verify status before going anywhere near it.

There is also a basic biological mismatch worth stating plainly. SS-31's demonstrated value is in rescuing damaged or aged mitochondria. A healthy, endurance-trained athlete already has dense, highly efficient mitochondria — that is literally what training builds. A drug whose mechanism is "make impaired mitochondria work better" has the least to offer the population with the least impairment. For where SS-31 and the rest of the field actually land on evidence, see our pillar guide to peptides for recovery and healing.

Bottom Line

SS-31/elamipretide is the most legitimately validated peptide in this category — and that validation is also exactly what exposes the hype. It is a real, mechanistically elegant cardiolipin-stabilizing mitochondrial drug that, in September 2025, earned the first-ever FDA approval for Barth syndrome and became the first approved mitochondria-targeted therapeutic. In aged mice it rapidly restores mitochondrial function and exercise capacity. Both of those facts are true.

But the approval is for an ultra-rare childhood disease, not for endurance; the impressive endurance data is in old animals correcting a deficit, not in healthy athletes; and the one large, rigorous human trial of walking capacity and fatigue — MMPOWER-3 — failed. There is zero controlled evidence that SS-31 improves performance, endurance, or recovery in healthy people, the approved product is not what's being sold to athletes, and athletic use is unproven off-label experimentation. Treat any confident "SS-31 boosted my endurance" claim as anecdote, not evidence. For how SS-31 stacks up against the rest of the field and which providers are actually worth considering, see our ranking of the best recovery peptide providers.